Rationale and design of the Anti-Xa Therapy to Lower...

Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome

C. Michael Gibson, Jessica L. Mega, Paul Burton, Shinya Goto, Freek Verheugt, Christoph Bode, Alexei Plotnikov, Xiang Sun, Nancy Cook-Bruns, Eugene Braunwald
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
161
Year:
2011
Language:
english
Pages:
65535
DOI:
10.1016/j.ahj.2011.01.026
File:
PDF, 428 KB
english, 2011
Conversion to is in progress
Conversion to is failed